![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, March 13, 2024 12:07:48 AM
SAVE
Legislation pushes for a delay in placing phosphate binders in the ESRD payment bundle
Add topic to email alerts
Key takeaways:
The Kidney Patient Act would delay placement of oral phosphate binders into the dialysis payment bundle.
Binders would be placed in the bundle if an injectable version receives FDA approval.
Congress is reviewing legislation that would delay inclusion of oral phosphate binders into the End-Stage Renal Disease Prospective Payment System bundled payment system.
NNI0324Carter_Graphic_01
CMS currently has plans to include oral binders in the bundle by Jan. 1, 2025, but the Kidney Patient Act (H.R. 5074), sponsored by U.S. Rep. Earl L. “Buddy” Carter, R-Ga., would amend the American Taxpayer Relief Act of 2012 to delay inclusion of the binders until 2033.
“Ensuing that the pending inclusion of oral-only drugs in the [End-Stage Renal Disease] Prospective Payment System (PPS) bundle meets the needs of the ESRD community is a priority for Kidney Care Partners, so we’re encouraged by the recent activity in the House of Representatives on this policy,” Mahesh Krishnan, MD, MPH, MBA, FASN, chair of Kidney Care Partners (KCP), told Healio.
“Without congressional action, this harmful policy would exacerbate the challenges the kidney community already faces, including diminished access to innovative therapies, insufficient reimbursement and limited or nonexistent choice of insurance coverage for patients,” KCP, a kidney community advocacy group, said in a press release.
According to language in the bill, placement of oral drugs indicated for the “reduction, management or control of the serum phosphate of an individual” would be delayed until 2033 unless “an intravenous drug indicated for the reduction, management or control of the serum phosphate of an individual has been approved by the [FDA].”
The General Accounting Office (GAO) released a report last November reviewing plans by CMS to include oral phosphate binders in the PPS by 2025. The report notes that dialysis organizations interviewed by the GAO “expressed concerns that the modified bundled payment may not fully account for the costs of acquiring, shipping and dispensing phosphate binders.”
References:
Recent UNCY News
- Unicycive Therapeutics Granted Patent on UNI-494 to Treat Acute Kidney Injury by the United States Patent and Trademark Office (USPTO) • GlobeNewswire Inc. • 07/17/2024 11:03:00 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 07/17/2024 04:15:18 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 07/16/2024 02:31:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/15/2024 08:15:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/15/2024 08:15:11 PM
- Unicycive Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 3rd Annual Kidney Virtual Conference • GlobeNewswire Inc. • 07/11/2024 11:03:00 AM
- Unicycive Therapeutics Announces Initial Positive Patient Satisfaction Findings from Pivotal Clinical Trial of Oxylanthanum Carbonate (OLC) • GlobeNewswire Inc. • 07/10/2024 11:03:00 AM
- Unicycive Therapeutics Joins Russell Microcap® Index • GlobeNewswire Inc. • 07/01/2024 11:03:00 AM
- Unicycive Therapeutics Achieves Study Objective in Oxylanthanum Carbonate (OLC) Pivotal Clinical Trial • GlobeNewswire Inc. • 06/25/2024 11:30:00 AM
- Unicycive Therapeutics Delivers Multiple Presentations on Oxylanthanum Carbonate (OLC) and UNI-494 at the European Renal Association Congress • GlobeNewswire Inc. • 05/28/2024 11:03:00 AM
- Unicycive Therapeutics to Participate in a Fireside Chat at the Lytham Partners Spring 2024 Investor Conference • GlobeNewswire Inc. • 05/23/2024 11:03:00 AM
- Unicycive Therapeutics Presents Bioequivalence Data on Oxylanthanum Carbonate (OLC) at the National Kidney Foundation Spring Clinical Meeting • GlobeNewswire Inc. • 05/15/2024 11:03:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 08:28:00 PM
- Unicycive Announces First Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/13/2024 08:16:34 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2024 08:06:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/08/2024 08:05:39 PM
- Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference • GlobeNewswire Inc. • 04/10/2024 11:03:00 AM
- Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 03/28/2024 08:15:00 PM
- Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress • GlobeNewswire Inc. • 03/25/2024 11:03:00 AM
- Unicycive Announces $50 Million Private Placement • GlobeNewswire Inc. • 03/14/2024 11:03:00 AM
- Unicycive Therapeutics Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT Conference • GlobeNewswire Inc. • 03/13/2024 11:03:00 AM
- Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC) • GlobeNewswire Inc. • 03/07/2024 09:12:00 PM
- Unicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 by the U.S. Food and Drug Administration for the Prevention of Delayed Graft Function in Kidney Transplant Patients • GlobeNewswire Inc. • 03/04/2024 12:03:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 09:06:09 PM
- Unicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical Meeting • GlobeNewswire Inc. • 02/14/2024 12:03:00 PM
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM